CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 30 enrolled
Drug / intervention
0.03% E6201 +12 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01268527
NCT01268527Phase 2Completed
CompareCT.gov

A 12-Day Randomized, Blinded, Vehicle and Active Comparator-Controlled Study to Determine the Efficacy and Safety of Six Concentrations of Topical E6201 Gel in Subjects With Psoriasis Vulgaris

Eisai Limited·interventional·Posted Dec 31, 2010·Updated Jun 11, 2021

In Brief

A Phase 2 clinical trial evaluating 0.03% E6201, 0.1% E6201, and 10 other interventions for Psoriasis Vulgaris. Completed, enrolled 30 participants across 1 site.

Detailed Summary

The purpose of this study is to investigate the efficacy, safety, tolerability and the concentration/response relationship of E6201 in subjects with psoriasis vulgaris.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis Vulgaris
CountriesGermany
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 31, 2010
Enrollment StartMar 15, 2010
Primary CompletionDec 11, 2010
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 15.5 years ago

Interventions

0.03% E6201drug

Topical 0.03% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.

0.1% E6201drug

Topical 0.1% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.

0.2% E6201drug

Topical 0.2% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.

0.005% E6201drug

Topical 0.005% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.

0.01% E6201drug

Topical 0.01% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.

0.05% E6201drug

Topical 0.05% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.

Placebo - 0.03% gel vehicleother

Topical 0.03% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.

Placebo - 0.1% gel vehicleother

Topical 0.1% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.

Placebo - 0.2% gel vehicleother

Topical 0.2% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.

Placebo - 0.05% gel vehicleother

Topical 0.005% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.

Placebo - 0.01% gel vehicleother

Topical 0.01% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.

Placebo - 0.05% gel vehicleother

Topical 0.05% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.

Calcipotrienedrug

Topical 0.005% calcipotriene (positive control) was applied once daily to individual specific regions of the psoriatic plaque.